SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Marcourakis, T.
Right arrow Articles by da Motta Singer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcourakis, T.
Right arrow Articles by da Motta Singer, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder

T. Marcourakis

Departamento de Farmacologia, Instituto de Ciências Biomédicas; Centro de Investigações em Neurologia, Hospital das Clínicas/FMUSP (LIM-15), tmarcour{at}usp.br

C. Gorenstein

Departamento de Farmacologia, Instituto de Ciências Biomédicas; Instituto de Psiquiatria, Hospital das Clínicas/FMUSP (LIM-23)

R. T. Ramos

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP (LIM-23)

J. da Motta Singer

Instituto de Matemática e Estatística, Universidade de São Paulo, Brazil

Several placebo-controlled trials have shown the effcacy of clomipramine (CMI) in panic disorder. However, none has investigated the relationship between CMI, and desmethylclomipramine (DCMI) plasma levels, and outcome. In this trial, 41 patients meeting the DSM-III-R criteria for panic disorder with/without agoraphobia received 50-200 mg of CMI daily in a single-blind, flexible dose regimen for 14 weeks. At the end of treatment, 97% of the patients were free of panic attacks. Patients were classified into two groups of improvement according to the panic symptom items of the `Patient-Rated Anxiety Scale'. A repeated-measures analysis of variance suggested a significant association between outcome and serum DCMI level/daily dose ratio as well as total serum level/daily dose. Patients with intense improvement showed DCMI and total serum levels lower than those with moderate improvement. The results indicate the importance of monitoring clomipramine and desmethylclomipramine serum levels in this disorder.

Key Words: clomipramine • desmethylclomipramine • panic disorder • plasma levels

Journal of Psychopharmacology, Vol. 13, No. 1, 40-44 (1999)
DOI: 10.1177/026988119901300105
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
S. C. de Carvalho, T. Marcourakis, R. Artes, and C. Gorenstein
Memory performance in panic disorder patients after chronic use of clomipramine
J Psychopharmacol, May 1, 2002; 16(3): 220 - 226.
[Abstract] [PDF]


Advertisement